Overview

Mercy Health is committed to medical research and clinical trials for patients suffering from leukemia, lymphoma and other blood cancers. From bone marrow transplants to trials for patients with polycythemia vera, see our listing of ongoing clinical trials and medical studies below to see if you’d be a possible candidate for participation.

Bone Marrow Transplant

Myelodysplastic Syndrome (MDS)
Older Adult MDS Allo (50-75 Years old)
Study Number: BMT CTN 1102
Protocol Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
Status: Open
Principal Investigator: James Essell, M.D.
To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Leukemia

Acute Myeloid Leukemia (AML)
Newly Diagnosed AML In Older Adults (60-Years-Old)
Study Number: E2906
Protocol Title: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (Age>/=60 Years)
Status: Open
Principal Investigator: E. Randolph Broun, M.D.
To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Acute Myeloid Leukemia (AML)
Newly Diagnosed AML In Younger Adults (18–60-Years-Old)
Study Number: S1203
Protocol Title: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Status: Open
Principal Investigator: James Essell, M.D.
To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Acute Lymphoblastic Leukemia
(ALL Philadelphia +) (18 Years and Older)
Study Number: CALGB 10701
Protocol Title: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Open
Principal Investigator: James Essell, M.D.
To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Lymphoma

CLL
A Randomized Phase III Study of Ibrutinib (PCI-32765) based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Study Number: NCT02048813
Please call 419-251-4919 to learn more.

Newly Diagnosed T-Cell Lymphoma (18 Years and Older)
Study Number: SGN35-014
Protocol Title: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Status: Open
Principal Investigator: Miguel Islas-Ohlmayer, M.D.
To learn more, please call The Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Relapsed/Refractory Hodgkin’s Disease (18 Years and Older)
Study Number: SGN35-016
Protocol Title: Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Status: Open
Principal Investigator: Miguel Islas-Ohlmayer, M.D.
To learn more, please call The Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

Hodgkin Lymphoma
Phase II Trial of Response-Adapted therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL) 
Study Number: NCT01118026
Please call 419-251-4919 to learn more.

Multiple Myeloma
Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis
Study Number: NCT01408225
Please call 419-251-4919 to learn more.

PCV
Prospective Non International Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices
Study Number: NCT 02252159
Please call 419-251-4919 to learn more.

Supportive Care

CMV Prophylaxis
Adult Allogeneic Stem Cell Transplant Recipients Aged ≥ 18 Years-Old
Study Number: CMX001-301
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMVseropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Status: Open
Principal Investigator: James Essell, M.D.
To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482.

If you believe that you would be a strong candidate for one of our blood cancer clinical trials, please reach out to the contacts listed above. Participating in medical trials gives you access to new or emerging treatment options that are not yet widely available, and allows you to help push medical research forward in the process.

Why Choose Mercy Health?
Mercy Health physicians and healthcare professionals are conducting medical research to help patients live healthier and longer. They are committed to making lives better—mind, body and spirit.